Prevention

The SRN prevention Clinical Study Group will identify research gaps in knowledge and evidence related to stroke prevention, propose study questions, and, in some cases, design and lead individual studies.

The CSG will also consider and offer advise on submitted academic and commercial studies during their design stage, whilst taking account of other planned and ongoing studies. The remit of the CSG will be to cover both primary and secondary prevention.

Primary prevention studies will be those where stroke is the primary outcome (but not where it is part of a composite vascular outcome).

Secondary prevention studies will cover both ischaemic and haemorrhagic stroke, and asymptomatic and symptomatic disease.

Haemorrhage will encompass all pathological types and regions of the brain (parenchymal, subarachnoid, cavernomatous, arteriovenous malformation) but will exclude bleeding following trauma.

Prevention studies may either be observational, or randomised and controlled, in nature, and may involve medical, surgical and neuroradiological interventions. The CSG will meet regularly by teleconference and face-to-face, and will liaise closely with the acute, rehabilitation and community CSGs.